You just read:

ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK

News provided by

ProNAi Therapeutics Inc.

27 Sep, 2016, 07:00 ET